Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
$21.39
$0.12(0.87%)
At close: 4:00 PM EST
$21.39
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$8.58 - $22.73
Previous CloseN/A
Volume201.89K
Average Volume (3M)1.43M
Market Cap
$1.86B
Enterprise Value$1.24B
Total Cash (Recent Filing)$454.17M
Total Debt (Recent Filing)$345.43M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Mar 09, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding86,914,840
10 Day Avg. Volume1,157,809
30 Day Avg. Volume1,426,469
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.93
Price to Sales (P/S)47.80
P/FCF Ratio-4.12
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue11.13
Enterprise Value/Gross Profit12.06
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$39.11Price Target Upside82.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durability And Role In Post-transplant MaintenanceDurable responses observed in trials and routine care, plus compatibility with common supportive medications, support adoption of Revuforj as a post-transplant maintenance backbone that could extend treatment duration and revenue per patient.
Physician Adoption And Real-world UptakeStrong clinician enthusiasm and expanding use of Revuforj in community, combination, and transplant-bridging settings indicates growing prescription momentum and broader frontline market penetration.
Regulatory Expansion And Market ReachFDA approval for relapsed or refractory NPM1-mutated AML, together with approval in KMT2A-rearranged disease, materially increases the addressable patient population and reinforces a first-mover commercial advantage.
Bears Say
Investor Sentiment And Market VolatilityShare-price pressure following the expanded boxed warning demonstrates market sensitivity to safety language, which could weigh on valuation and increase financing or execution risk despite commercial progress.
Maintenance Dosing UncertaintyNeed to define an optimal maintenance dosing regimen creates clinical execution risk that could slow uptake in maintenance and earlier-line settings until standardized guidance is available.
Regulatory Safety Warning (QTc Risk)Inclusion of QTc prolongation in the boxed warning raises safety and monitoring concerns that may lead to more conservative prescribing and additional payer scrutiny.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $22.73 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.86B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Mar 09, 2026 which is in 57 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Nov 03, 2025. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.024.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.6.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 86,914,840 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 11.555%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.11 (82.84% Upside)
$39.11 (82.84% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 342.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.88%
12-Months-Change
Fundamentals
Return on Equity
-129.32%
Trailing 12-Months
Asset Growth
29.59%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
SNDX Company Deck
SNDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Syndax showed strong revenue growth and successful product launches, with Revuforj expanding its market potential significantly through an FDA approval. However, temporary treatment pauses and higher gross to net adjustments posed challenges in realizing full revenue potential.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$39.11
▲(82.84% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
13.77% Mutual Funds
47.94% Other Institutional Investors
23.23% Public Companies and Individual Investors